The road leading to Nasirotu, Nasele, Naseuvou, and Delailasakau will remain closed until tomorrow, with the FRA confirming that only emergency transport will be available at both ends of the closure.

a Represents net earnings attributable to AbbVie Inc. Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time gain of $169 ...

The best ADC for each patch changes by the minute, with the meta and item adjustments constantly adding variance to the bot lane. Recommended Videos ADCs come in all shapes and sizes, and you must ...

The launch of the company's new ovarian cancer drug Elahere is going well. Botox continues to generate billions of dollars each year. Sales of migraine drugs Ubrelvy and Qulipta are growing at ...

The rule itself would have little impact on Class I and II railroads: They’re already meeting or exceeding the proposed inspection frequency with their various track geometry measurement systems, the ...

Elahere addresses the gap in effective medications for those platinum-resistant cancers which express high levels of folate receptor α (FRα). To determine your eligibility for Elahere, your doctor ...

A continuation of strong growth trends is my baseline assumption for the two products. Addition of Elahere is driving the return to growth of the oncology portfolio For the oncology segment ...

The primary objective of the present study was to assess the anti-tumor activity of a combination of trastuzumab with carboplatin and paclitaxel in patients with recurrent or refractory ovarian ...

the most recent being Elahere for multiple gynecological tumors in 2022. With an estimated value around USD 10 Billion in 2023, witnessing 35% rise from the previous year, the global cancer ADC ...

ADC are responsible for the majority of the damage output, yet the role’s importance has undergone several shifts over the past years. While the marksmen were considered the most OP roles in some ...

More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study. The FDA's label for Elahere (mirvetuximab soravtansine ...

The antibody-drug conjugate (ADC), which will remain on the market in other indications, is a pillar of Gilead’s cancer portfolio. Trodelvy was approved for the indication under accelerated review in ...